Eli Lilly 2015 Annual Report Download - page 118
Download and view the complete annual report
Please find page 118 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108 -
109 -
110 -
111 -
112 -
113 -
114 -
115 -
116 -
117 -
118 -
119 -
120 -
121 -
122 -
123 -
124 -
125 -
126 -
127 -
128 -
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
 |
 |
P2
Proxy Statement Overview
General Information
This overview highlights information contained elsewhere in this proxy statement. It does not contain all the
information you should consider, and you should read the entire proxy statement carefully before voting.
Meeting: Annual Meeting of Shareholders Date: May 2, 2016
Time: 11:00 a.m. EDT Location: The Lilly Center Auditorium
Lilly Corporate Center
Indianapolis, Indiana 46285
Record Date: February 26, 2016
Items of Business: Item 1: Election of the five directors listed in this proxy statement to serve
three-year terms.
Item 2: Approval, by non-binding vote, of the compensation paid to the
company's named executive officers.
Item 3: Ratification of Ernst & Young LLP as the principal independent auditors
for 2016.
Item 4: If presented, a shareholder proposal seeking a report regarding how we
select the countries in which we operate or invest.
What Is New In This Year's Proxy Statement
In 2015, we returned to revenue and earnings growth, launched a number of new products, made significant
late-stage pipeline progress, and delivered strong returns to shareholders. As a result, we resumed annual
increases to base salaries and delivered incentive compensation reflective of our performance.
Additionally, we restated our executive officers' share ownership requirements from a fixed number of shares
to a multiple of annual base salary for all executives, excluding the CEO. The CEO's requirement remains six
times annual base salary.
In February 2016, we welcomed Juan R. Luciano to the board. Mr. Luciano is the Chairman and CEO of
Archer Daniels Midland Company.
Highlights of 2015 Company Performance
The following provides a brief look at our 2015 performance in three dimensions: operating performance,
innovation progress, and returns to shareholders. See our 2015 annual report on Form 10-K for more details.
Operating Performance
In 2015, we returned to revenue and earnings growth following a multi-year period of patent expirations. This
growth was led by several pharmaceutical products, including Cyramza, Trulicity and Humalog, as well as
Erbitux due to the transfer of commercialization rights in North America. This growth was partially offset by the
residual impact of the loss of exclusivity for Cymbalta and Evista.
Performance highlights included:
• 2015 revenue increased 2 percent to approximately $20 billion.
• 2015 earnings per share (EPS) increased 1 percent on a reported basis to $2.26, and increased 13
percent on a non-GAAP basis to $3.43.
*A reconciliation of GAAP and externally reported non-GAAP measures is included in Appendix A.